5 longitudinal fatigue trajectories have been identified in this patient population.
-
Early-stage breast cancer: 2 of 3 have posttherapy low-level fatigue up to 18 months -
The latest stories you need to know.
-
First-ever trial of home smear tests in England.
-
Tests can help stratify women with breast cancer into different groups according to recurrence risk
-
Investment needed to bring down pancreatic cancer death rates.
-
RCC: SBRT with TKI is tolerable and prolongs OS Patients with oligometastasis and favorable or intermediate-risk disease benefit the most.
-
ASCO-GU 2021 — mCRPC: apalutamide prolongs r-PFS Final analysis of the phase 3 ACIS trial.
-
ER+ metastatic breast cancer: real-world, RCT results in synch for fulvestrant PFS was 14.6 months and OS was 43.1 months in postmenopausal women.
-
The latest stories you need to know.
-
Associations between occupation and heavy drinking differ in men and women.
-
ASCO-GU 2021 — As PSA screening declines, metastatic prostate cancer incidence climbs US states with larger screening declines have larger incidence increases.
-
MIBC: neoadjuvant cabazitaxel-cisplatin combo yields good response The combination is well tolerated and warrants further prospective evaluation.
-
ASCO-GU 2021 — mCRPC: saracatinib-docetaxel combo disappoints Findings from a phase 1/2 trial.
-
Esophageal cancer: minimally invasive surgery shows long-term promise Fewer postoperative complications seen with hybrid minimally invasive esophagectomy.